Ventyx Biosciences Beheer

Hoe is Raju Mohan's beloning veranderd ten opzichte van Ventyx Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$153m
Jun 30 2024	n/a	n/a	-US$171m
Mar 31 2024	n/a	n/a	-US$193m
Dec 31 2023	US$9m	US$596k	-US$193m
Sep 30 2023	n/a	n/a	-US$181m
Jun 30 2023	n/a	n/a	-US$158m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$4m	US$567k	-US$108m
Sep 30 2022	n/a	n/a	-US$91m
Jun 30 2022	n/a	n/a	-US$73m
Mar 31 2022	n/a	n/a	-US$69m
Dec 31 2021	US$15m	US$423k	-US$85m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$79m
Mar 31 2021	n/a	n/a	-US$65m
Dec 31 2020	US$68k	US$37k	-US$28m

Compensatie versus markt: De totale vergoeding ($USD 9.41M ) Raju } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.45M ).

Compensatie versus inkomsten: De vergoeding van Raju is gestegen terwijl het bedrijf verliesgevend is.

CEO

Raju Mohan (66 yo)

6yrs

Tenure

US$9,411,949

Compensatie

Dr. Raju S. Mohan, Ph.D. founded Ventyx Biosciences, Inc. in November 2018 and serves as its Chief Executive Officer and Director since then and serves as its President since November 22, 2023. Dr. Mohan h...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sheila Gujrathi	Executive Chairperson	3.5yrs	US$486.29k	0% $ 0
Raju Mohan	Founder	6yrs	US$9.41m	3.08% $ 5.8m
John Nuss	Chief Scientific Officer	5.8yrs	US$3.89m	0.37% $ 702.2k
Roy Gonzales	Interim Principal Financial Officer & Principal Accounting Officer	less than a year	geen gegevens	0.0010% $ 2.0k
Matthew Moore	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Mark Forman	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VTYX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sheila Gujrathi	Executive Chairperson	3.5yrs	US$486.29k	0% $ 0
Raju Mohan	Founder	6yrs	US$9.41m	3.08% $ 5.8m
Allison Hulme	Independent Director	1.8yrs	US$834.42k	0% $ 0
Somasundaram Subramaniam	Independent Director	6yrs	US$417.35k	geen gegevens
Alexa Kimball	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Krueger	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
Bruce Sands	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
Emma Guttman-Yassky	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
William White	Independent Director	3.5yrs	US$416.29k	0% $ 0
Onaiza Cadoret-Manier	Independent Director	1.8yrs	US$837.34k	0% $ 0

3.5yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VTYX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Ventyx Biosciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Founder recently bought US$960k worth of stock

Ventyx Biosciences, Inc. Announces Executive Appointments

Ventyx Biosciences, Inc. Announces CFO Changes

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

Ventyx Biosciences, Inc., Annual General Meeting, Jun 05, 2024

Founder recently sold US$125k worth of stock

Recent updates

Founder recently bought US$960k worth of stock

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Ventyx Biosciences, Inc. Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.

Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.

Ventyx Biosciences, Inc. Announces Executive Appointments

Ventyx Biosciences, Inc. Announces CFO Changes

Price target decreased by 10.0% to US$10.00

Price target increased by 9.8% to US$11.75

New major risk - Revenue and earnings growth

Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of Vtx958 in Participants with Moderately to Severely Active Crohn’S Disease

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)

Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

New major risk - Revenue and earnings growth

Ventyx Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Ventyx Biosciences, Inc., Annual General Meeting, Jun 05, 2024

Price target increased by 13% to US$10.90

Ventyx Pivots To Obesity Amid Transformation

Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in funding

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the Firm

Price target increased by 8.9% to US$9.67

New major risk - Revenue and earnings growth

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Ventyx: Too Risky Right Now After Some Poor Data

Founder recently sold US$125k worth of stock

Founder notifies of intention to sell stock

Ventyx Biosciences, Inc. Announces Executive Changes

New major risk - Revenue and earnings growth

Price target decreased by 26% to US$40.20

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative Colitis

Chief Business Officer notifies of intention to sell stock

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

President & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Ventyx Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New minor risk - Share price stability

President & Chief Medical Officer notifies of intention to sell stock

Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 Inhibitor

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

President & Chief Medical Officer exercised options and sold US$362k worth of stock

President & Chief Medical Officer exercised options and sold US$118k worth of stock

Ventyx Biosciences, Inc. to Report Q1, 2023 Results on May 11, 2023

Chief Financial Officer exercised options and sold US$968k worth of stock

Chief Financial Officer exercised options and sold US$207k worth of stock

Executive Chair exercised options and sold US$2.8m worth of stock

Price target increased by 7.8% to US$55.45

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Price target increased by 7.6% to US$55.50

Independent Director exercised options and sold US$969k worth of stock

Ventyx Biosciences, Inc. Announces Board Appointments

Founder recently sold US$1.7m worth of stock

President & Chief Medical Officer exercised options and sold US$1.4m worth of stock

Chief Scientific Officer recently sold US$1.2m worth of stock

Chief Financial Officer exercised options and sold US$1.3m worth of stock

Founder recently sold US$8.7m worth of stock

Ventyx Biosciences, Inc Announces Dosing of the First Patient in the Phase 2 Serenity Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

High number of new directors

Ventyx Biosciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ventyx Biosciences: Not Chasing This Rally

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Ventyx Biosciences, Inc. Announces Positive Data from its Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of VTX958, Novel and Selective Allosteric TYK2 Inhibitor

Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06